Increased risk of gastrointestinal adverse effects under SSRI/NSAID combination may be due to pharmacokinetic interactions [1] (multiple letters)

British Journal of Clinical Pharmacology

Volumn 59, Issue 1, 2005, Pages 118-119

  Zullino, Daniele Fabio ^a   Khazaal, Yasser ^a   De Jong, Jeroen C F ^b   Brouwers, Jacobus R B J ^b   De Jong Van Den Berg, Lolkje T W ^b  

^a DEPT UNIV DE PSYCHIATRIE ADULTE   (Switzerland)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACECLOFENAC; AMITRIPTYLINE; ANTIULCER AGENT; CELECOXIB; CITALOPRAM; CLOMIPRAMINE; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450 2C9; DICLOFENAC; FLUOXETINE; FLUVOXAMINE; IBUPROFEN; INDOMETACIN; KETOPROFEN; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PAROXETINE; PIROXICAM; ROFECOXIB; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BLEEDING; DRUG BLOOD LEVEL; DRUG INTERACTION; DRUG METABOLISM; DRUG USE; GASTROINTESTINAL SYMPTOM; GENETIC POLYMORPHISM; HUMAN; LETTER; PHARMACOGENETICS; PRIORITY JOURNAL; RISK;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ARYL HYDROCARBON HYDROXYLASES; DRUG COMBINATIONS; GASTROINTESTINAL DISEASES; HUMANS; SEROTONIN UPTAKE INHIBITORS;

EID: 11144300165     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2005.2212_1.x     Document Type: Letter

References (0)